ARG2

Across TCGA pan-cancer cohorts, ARG2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARG2 data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ARG2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARG2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and PDAC are the cancer types where ARG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.953	0.570	.001	39	view →
HNSC	DFS	Quartile	III,IV	0.853	0.409	.005	38	view →
PDAC	DFS	Quartile	II,III,IV	0.486	0.913	.010	14	view →
LUAD	DFS	Median	III,IV	0.767	0.247	.037	4	view →
CCRCC	OS	Tertile	II,III,IV	0.546	1.000	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARG2–LSCC (OS)

Open the LSCC breakdown →